Signal Genetics has reported the results of a new study, entitled “Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis,” at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco. The poster confirms prognostic capabilities of the DiagnoCure Inc Previstage GCC Colorectal Cancer Staging Test in patients with colon cancer.

Based on the pooled individual data analysis on 310 patients and involving researchers and collaborators from several centers, the study shows that the GCC levels allow an effective stratification of patients between those that are essentially cured and those at high risk of disease recurrence. The five-year recurrence risks were estimated at 11% and 32% for the low- and high-risk groups, respectively. Higher detection levels of GCC in lymph nodes were also significantly associated with increased risk of all-cause mortality, disease-specific survival, and disease-free survival.

Previstage GCC is currently the only colorectal cancer staging test on the market that provides prognostic information based on the tumor burden measured at the molecular level in the lymph nodes. Tumor burden in the lymph nodes has become more widely recognized by treating physicians as a key prognostic factor to determine the risk of recurrence of cancer patients, and hence, to determine which patients might benefit most from adjuvant chemotherapy and which could be safely managed without chemotherapy.

Source: DiagnoCure Inc